In addition, EphA2 was recently shown to demonstrate a similar trend in lung cancer in which patients expressing low levels of EphA2 had a median survival that was over threefold longer than in patients with strong EphA2 expression [9]. This evidence concerns the gene EPHA2 and lung carcinoma.